HANSHOW
27.3.2024 10:56:30 CET | Business Wire | Press release
From March 13th to 15th, the 24th China Retail Expo was held at Shanghai's National Convention and Exhibition Center. Under the theme "Green Digitalization and GenAI for Sustainable Retail," Hanshow debuted its pioneering GenAI product strategy, marking a significant leap forward in retail's AI era. The showcase included the upgraded Hanshow Polaris Pro series electronic shelf labels (ESL) and a new green digital store solution, reaffirming Hanshow's dedication to providing retailers with cutting-edge technologies for enhanced efficiency, improved shopper experiences, and sustainable practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320389359/en/
The breakthrough of Generative Pre-trained Transformer 3 (GPT-3) technology, represented by represented by ChatGPT, has expanded the boundaries of all industries. Hanshow is Microsoft’s global strategy partner in the retail industry since 2023 and is one of the first to incorporate GenAI technology in retail scenarios using Azure OpenAI (AOAI).
At the event, Eason Tong, Dean of the Hanshow Retail Research Institute, announced Hanshow's first GenAI solution for retail business operations based on strategic cooperation with Microsoft. For retailers, Hanshow uses OpenAI's large model capabilities integrated with massive digital retail data to create the industry's first automated content (copy + image) generation intelligent application solution - the Hanshow Store Marketing Assistant.
The GenAI solution released by Hanshow relies on open source GPT-4 text output and Dall-E3 image output and can generate commodity POP posters, marketing atmosphere posters, and product copy through dialogue interaction. The internal integration of Hanshow's product ecosystem allows the generated materials to be uploaded and shown on the Hanshow Lumina Screen and upcoming large-sized colorful electronic paper posters with one click.
With the Hanshow Store Marketing Assistant, stores can easily generate a variety of creatively designed marketing materials to vividly portray product selling points while controlling marketing costs and improving sales. Whether it is a store operator or a brand owner, retailers can use the solution to reduce creative work from several hours to a few minutes.
"Hanshow is dedicated to offering retailers a retail media network solution that diversifies income streams. Leveraging generative AI for content, personalization, and impact assessment, we support future store media networks comprehensively," said Tong.
Microsoft and its ecosystem have supported Hanshow in building a digital store solution based on Azure OpenAI capabilities, and the two parties are deepening their cooperation and accelerating the landing of generative AI in global physical retail scenarios.
Microsoft and Hanshow jointly held a high-level roundtable forum to explore revolutionary omnichannel GenAI retail applications and trends and the green development and digital transformation of the retail industry.
"GenAI's remarkable capabilities are revolutionizing various industries. We're delighted to see Hanshow, Microsoft's global strategic partner, leveraging Azure OpenAI technology to introduce generative AI into physical retail. As a pioneer in retail digitalization, Hanshow combines industry insights with GenAI to present innovative digital store solutions," stated Frank Kong, Microsoft China's General Manager of Retail Consumer Goods.
Coming up, Hanshow and Microsoft’s GenAI marketing solutions for consumers will also be unveiled at the NRF exhibition in Singapore in June 2024, covering the four areas of store operations, consumer experience, store media, and green energy.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320389359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom